These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 2905759)

  • 1. Haematological adverse effects of histamine H2-receptor antagonists.
    Aymard JP; Aymard B; Netter P; Bannwarth B; Trechot P; Streiff F
    Med Toxicol Adverse Drug Exp; 1988; 3(6):430-48. PubMed ID: 2905759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions and interactions with H2-receptor antagonists.
    Penston J; Wormsley KG
    Med Toxicol; 1986; 1(3):192-216. PubMed ID: 2878343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety issues relating to long-term treatment with histamine H2-receptor antagonists.
    Sabesin SM
    Aliment Pharmacol Ther; 1993; 7 Suppl 2():35-40. PubMed ID: 8103374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor.
    Ruscin JM; Page RL; Valuck RJ
    Ann Pharmacother; 2002 May; 36(5):812-6. PubMed ID: 11978157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the safety profile of the H2-receptor antagonists.
    Hansten PD
    DICP; 1990 Nov; 24(11 Suppl):S38-41. PubMed ID: 1980183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reactions to H2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status.
    Andersen M; Schou JS
    Pharmacol Toxicol; 1991 Oct; 69(4):253-8. PubMed ID: 1683484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic effects of drugs used in the treatment of peptic ulcer disease.
    Lewis JH
    Am J Gastroenterol; 1987 Oct; 82(10):987-1003. PubMed ID: 2889354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of histamine H2-receptor antagonists on the hepatic elimination of drugs].
    Klotz U; Reimann I
    Klin Wochenschr; 1983 Jul; 61(13):625-32. PubMed ID: 6136626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famotidine: a notable lack of drug interactions.
    Humphries TJ
    Scand J Gastroenterol Suppl; 1987; 134():55-60. PubMed ID: 2889260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of various histamine H2-receptor antagonists on gastrointestinal motility and gastric emptying].
    Ohira Y; Hanyu N; Aoki T; Hashimoto Y; Iikura M; Fukuda S
    J Smooth Muscle Res; 1993 Aug; 29(4):131-42. PubMed ID: 7907895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.
    Cotton RB; Shah LP; Poole SD; Ehinger NJ; Brown N; Shelton EL; Slaughter JC; Baldwin HS; Paria BC; Reese J
    J Mol Cell Cardiol; 2013 Jun; 59():86-94. PubMed ID: 23454087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells.
    Hahm KB; Park IS; Kim HC; Lee KJ; Kim JH; Cho SW; Lee SI
    Int J Immunopharmacol; 1996; 18(6-7):393-9. PubMed ID: 9024941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-oxidant properties of H2-receptor antagonists. Effects on myeloperoxidase-catalysed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system.
    van Zyl JM; Kriegler A; van der Walt BJ
    Biochem Pharmacol; 1993 Jun; 45(12):2389-97. PubMed ID: 8101078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists.
    Knodell RG; Holtzman JL; Crankshaw DL; Steele NM; Stanley LN
    Gastroenterology; 1982 Jan; 82(1):84-8. PubMed ID: 6118314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
    Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of H2-receptor antagonists: current status of famotidine.
    Levine JB
    J Int Med Res; 1989; 17 Suppl 1():48A-53A. PubMed ID: 2566543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.